Efficacy of levosimendan in patients with chronic heart failure: Does rhythm matter?

Yontar O. C., YILMAZ M. B., Yalta K., Tandogan I.

ANADOLU KARDIYOLOJI DERGISI-THE ANATOLIAN JOURNAL OF CARDIOLOGY, vol.10, no.4, pp.310-316, 2010 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 10 Issue: 4
  • Publication Date: 2010
  • Doi Number: 10.5152/akd.2010.088
  • Journal Name: ANADOLU KARDIYOLOJI DERGISI-THE ANATOLIAN JOURNAL OF CARDIOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.310-316
  • Keywords: Heart failure, levosimendan, atrial fibrillation, VENTRICULAR DIASTOLIC FUNCTION, FLOW PROPAGATION VELOCITY, CALCIUM SENSITIZER LEVOSIMENDAN, CAPILLARY WEDGE PRESSURE, M-MODE DOPPLER, ATRIAL-FIBRILLATION, RANDOMIZED-TRIAL, CARDIAC-FUNCTION, TISSUE DOPPLER, ECHOCARDIOGRAPHY
  • Dokuz Eylül University Affiliated: No

Abstract

Objective: Leyosimendan is a relatively new inotropic agent. Unlike other inotropic agents, Levosimendan does not increase cellular calcium intake, so that, does not cause intracellular calcium overload and related arrhythmias. Atrial fibrillation (AF) was shown to be an independent risk factor for mortality and morbidity in large heart failure (HF) trials. Heart failure induces AF, AF aggravates HF and therefore they generally coexist. We conducted a study to investigate if there is any differential effect of Levosimendan in HF patients with chronic AF and without AF.